Nonetheless, ANGPTL3 inhibitors can lower the concentrations of atherogenic particles independently of LDL receptor function and, hence, may be used in mixed hyperlipidemia and HoFH [13]. Here, ANGPTL3 is linked to Combined hyperlipidemia.